Search

Your search keyword '"Rog, David"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Rog, David" Remove constraint Author: "Rog, David" Publisher elsevier bv Remove constraint Publisher: elsevier bv
29 results on '"Rog, David"'

Search Results

2. Prevalence, Treatment and Correlates of Depression in Multiple Sclerosis

3. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study

6. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

7. Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)

8. The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications

12. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

13. Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy

14. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies

16. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

17. The Impact of Smoking Cessation on Multiple Sclerosis Disease Progression

19. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

23. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

24. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

25. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

26. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

29. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Catalog

Books, media, physical & digital resources